The Inflation Reduction Act, signed in August 2022, includes provisions that impact community pharmacy.

Please see below for some resources on the Inflation Reduction Act.

NCPA Comments

• Joint NCPA/APhA/ASCP/NASPA/ASHP letter calling on CMS to freeze the Medicare Drug Price Negotiation Program (February 2025)

• NCPA comments to Domestic Policy Council regarding concerns with the Medicare Drug Price Negotiation Program (January 2025)

• NCPA comments to CMS on its draft pharmacy agreements as part of the Medicare Drug Price Negotiation Program (January 2025)

• NCPA letter to the Department of Government Efficiency (DOGE) regarding recommendations for PBM reform and reforms to the Medicare Drug Price Negotiation Program (December 2024)

• NCPA comments to CMS on Medicare Drug Price Negotiation program draft forms (December 2024)

  • MTF DM Dispensing Entity and Third-Party Support Entity Enrollment Form

  • MTF DM Primary Manufacturer MFP Effectuation Plan Form

  • Complaint and Dispute Intake Form

NCPA Resources

• NCPA Medicare Drug Price Negotiation Program talking points (November 2024)

• NCPA member summary on CMS’ guidance on the Medicare Drug Price Negotiation Program (October 2024)

• NCPA member summary on CMS’ guidance on the Medicare Prescription Payment Plan (MPPP)/”co-pay smoothing” (July 2024)

Centers for Medicare
and Medicaid Services (CMS) Resources

• Implementation Timeline

• Inflation Reduction Act and Medicare

• Medicare Drug Price Negotiation

• Fact Sheet: Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2026

• Fact Sheet: Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2027